In vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against gram-negative bacilli
- PMID: 19382669
In vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against gram-negative bacilli
Abstract
We investigated in vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against Gram-negative bacilli. Piperacillin/tazobactam 8:1 lowered resistance for Escherichia coli, Serratia marcescens, Enterobactaer cloacae, Klebsiella pneumoniae and imipenem-susceptible Acinetobacter baumannii. When piperacillin was combined with sulbactam 2:1 or 4:1, resistance against E. coli, S. marcescens, E. cloacae, extended spectrum beta-lactamase (ESBL)-K. pneumoniae and A. baumannii were reduced. MIC90 of cefoperazone against S. marcescens, E. cloacae, ESBL-K. pneumoniae and A. baumannii were >128 mg/L. Addition of sulbactam 1:1 or 2:1 enhanced antimicrobial activities. Addition of sulbactam to piperacillin or cefoperazone enhanced antimicrobial activities of GNB.
Similar articles
-
In vitro activities of beta-lactam antibiotics alone and in combination with sulbactam against Gram-negative bacteria.Int J Antimicrob Agents. 2004 Jun;23(6):590-5. doi: 10.1016/j.ijantimicag.2003.10.008. Int J Antimicrob Agents. 2004. PMID: 15194130
-
Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.Braz J Infect Dis. 2000 Feb;4(1):22-8. Braz J Infect Dis. 2000. PMID: 10788842
-
[Changes of antimicrobial resistance among nonfermenting gram-negative bacilli isolated from intensive care units from 1994 to 2001 in China].Zhonghua Yi Xue Za Zhi. 2003 Mar 10;83(5):385-90. Zhonghua Yi Xue Za Zhi. 2003. PMID: 12820914 Chinese.
-
Comparative susceptibility profile of piperacillin/tazobactam against anaerobic bacteria.J Antimicrob Chemother. 1993 Jan;31 Suppl A:29-38. doi: 10.1093/jac/31.suppl_a.29. J Antimicrob Chemother. 1993. PMID: 8383654 Review.
-
beta-Lactamase inhibition and in vitro activity of sulbactam and sulbactam/cefoperazone.Clin Infect Dis. 1997 Mar;24(3):494-7. doi: 10.1093/clinids/24.3.494. Clin Infect Dis. 1997. PMID: 9114205 Review.
Cited by
-
In Vitro Antimicrobial Activity of Various Cefoperazone/Sulbactam Products.Antibiotics (Basel). 2020 Feb 12;9(2):77. doi: 10.3390/antibiotics9020077. Antibiotics (Basel). 2020. PMID: 32059590 Free PMC article.
-
Continuous infusion of ceftolozane-tazobactam resulted in high cerebrospinal fluid concentrations of ceftolozane in a patient with multidrug-resistant Pseudomonas aeruginosa meningitis.Infection. 2021 Apr;49(2):355-359. doi: 10.1007/s15010-020-01510-8. Epub 2020 Aug 29. Infection. 2021. PMID: 32862306
-
Correlation Between Cefoperazone/Sulbactam MIC Values and Clinical Outcomes of Escherichia coli Bacteremia.Infect Dis Ther. 2022 Oct;11(5):1853-1867. doi: 10.1007/s40121-022-00672-2. Epub 2022 Jul 22. Infect Dis Ther. 2022. PMID: 35864347 Free PMC article.
-
Drug concentrations in the serum and cerebrospinal fluid of patients treated with cefoperazone/sulbactam after craniotomy.BMC Anesthesiol. 2015 Mar 13;15:33. doi: 10.1186/s12871-015-0012-1. eCollection 2015. BMC Anesthesiol. 2015. PMID: 25798070 Free PMC article. Clinical Trial.
-
Model-Informed Drug Development of New Cefoperazone Sodium and Sulbactam Sodium Combination (3:1): Pharmacokinetic/Pharmacodynamic Analysis and Antibacterial Efficacy Against Enterobacteriaceae.Front Pharmacol. 2022 Jul 18;13:856792. doi: 10.3389/fphar.2022.856792. eCollection 2022. Front Pharmacol. 2022. PMID: 35924047 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
